Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation

Genes and Development

Volumn 29, Issue 6, 2015, Pages 658-671

  Roy, Nilotpal ^a   Malik, Shivani ^b   Villanueva, Karina E ^a   Urano, Atsushi ^a   Lu, Xinyuan ^b   Von Figura, Guido ^c   Scott Seeley, E ^b   Dawson, David W ^d   Collisson, Eric A ^b   Hebrok, Matthias ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brg1; Dedifferentiation; EMT; IPMN; Kras; Pancreatic cancer

Indexed keywords

BRG1 PROTEIN; K RAS PROTEIN; (+)-JQ1 COMPOUND; AZEPINE DERIVATIVE; DNA HELICASE; KRAS2 PROTEIN, MOUSE; NUCLEAR PROTEIN; PROTEIN P21; SMARCA4 PROTEIN, MOUSE; SOX9 PROTEIN, MOUSE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SOX9; TRIAZOLE DERIVATIVE;

ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL DEDIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVE SITE; EPIGENETICS; GENETIC TRANSCRIPTION; HEMATOLOGIC MALIGNANCY; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; ANIMAL; CARCINOMA, PANCREATIC DUCTAL; CELL TRANSFORMATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PANCREATIC NEOPLASMS; PATHOPHYSIOLOGY; TUMOR CELL CULTURE;

ANIMALS; AZEPINES; CARCINOMA, PANCREATIC DUCTAL; CELL TRANSFORMATION, NEOPLASTIC; DNA HELICASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS); SOX9 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS; TRIAZOLES; TUMOR CELLS, CULTURED;

EID: 84925249023     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.256628.114     Document Type: Article

References (62)

1. Bardeesy N, Cheng KH, Berger JH, Chu GC, Pahler J, Olson P, Hezel AF, Horner J, Lauwers GY, Hanahan D, et al. 2006. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 20: 3130-3146.
2. Buscarlet M, Krasteva V, Ho L, Simon C, Hebert J, Wilhelm B, Crabtree GR, Sauvageau G, Thibault P, Lessard JA. 2014. Essential role of BRG, the ATPase subunit of BAF chromatin remodeling complexes, in leukemia maintenance. Blood 123: 1720-1728.
3. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, et al. 2011. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 17: 500-503.
4. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, et al. 2011. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. NEngl JMed 364:1817-1825.
5. Dal Molin M, Hong SM, Hebbar S, Sharma R, Scrimieri F, de Wilde RF, Mayo SC, Goggins M, Wolfgang CL, Schulick RD, et al. 2012. Loss of expression of the SWI/SNF chromatin remodeling subunit BRG1/SMARCA4 is frequently observed in intraductal papillary mucinous neoplasms of the pancreas. Hum Pathol 43: 585-591.
6. De La O JP, Emerson LL, Goodman JL, Froebe SC, Illum BE, Curtis AB, Murtaugh LC. 2008. Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci 105: 18907-18912.
7. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et al. 2011. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146: 904-917.
8. De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, Helin K, Hornick JL, Mautner V, Kehrer-Sawatzki H, et al. 2014. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature 514: 247-251.
9. Elsasser HP, Lehr U, Agricola B, Kern HF. 1992. Establishment and characterisation of two cell lines with different grade of differentiation derived from one primary human pancreatic adenocarcinoma. Virchows Arch B Cell Pathol Incl Mol Pathol 61: 295-306.
10. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et al. 2010. Selective inhibition of BET bromodomains. Nature 468: 1067-1073.
11. Flowers S, Nagl NG Jr, Beck GR Jr, Moran E. 2009. Antagonistic roles for BRM and BRG1 SWI/SNF complexes in differentiation. J Biol Chem 284: 10067-10075.
12. Fujita H, Ohuchida K, Mizumoto K, Nakata K, Yu J, Kayashima T, CuiL, ManabeT, OhtsukaT, Tanaka M. 2010. a-Smoothmus- cle actin expressing stroma promotes an aggressive tumor biology in pancreatic ductal adenocarcinoma. Pancreas 39: 1254-1262.
13. Gazin C, Wajapeyee N, Gobeil S, Virbasius CM, Green MR. 2007 An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 449: 1073-1077.
14. Guerra C, Schuhmacher AJ, Canamero M, Grippo PJ, Verdaguer L, Perez-Gallego L, Dubus P, Sandgren EP, Barbacid M. 2007. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11: 291-302.
15. Habbe N, Shi G, Meguid RA, Fendrich V, Esni F, Chen H, Feldmann G, Stoffers DA, Konieczny SF, Leach SD, et al. Spontaneous induction of murine pancreatic intraepi- thelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad Sci 105: 18913-18918.
16. Helming KC, Wang X, Roberts CW. 2014. Vulnerabilities of mutant SWI/SNF complexes in cancer. Cancer Cell 26: 309-317.
17. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20: 1218-1249.
18. Hoffman GR, Rahal R, Buxton F, Xiang K, McAllister G, Frias E, Bagdasarian L, Huber J, Lindeman A, Chen D, et al. 2014. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc Natl Acad Sci 111: 3128-3133.
19. Ijichi H, Chytil A, Gorska AE, Aakre ME, Fujitani Y, Fujitani S, Wright CV, Moses HL. 2006. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-p signaling in cooperation with active Kras expression. Genes Dev 20: 3147-3160.
20. Inada A, Nienaber C, Katsuta H, Fujitani Y, Levine J, Morita R, Sharma A, Bonner-Weir S. 2008. Carbonic anhydrase II-posi- tive pancreatic cells are progenitors for both endocrine and exocrine pancreas after birth. Proc Natl Acad Sci 105: 19915-19919.
21. Ischenko I, Petrenko O, Hayman MJ. 2014. Analysis of the tumor- initiating and metastatic capacity of PDX1-positive cells from the adult pancreas. Proc Natl Acad Sci 111: 3466-3471.
22. Izeradjene K, Combs C, Best M, Gopinathan A, Wagner A, Grady WM, Deng CX, Hruban RH, Adsay NV, Tuveson DA, et al. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 11: 229-243.
23. Kadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, Ranish J, Crabtree GR. 2013. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet 45: 592-601.
24. Kopp JL, von Figura G, Mayes E, Liu FF, Dubois CL, Morris JP, Pan FC, Akiyama H, Wright CVE, Jensen K, et al. 2012. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell 22: 737-750.
25. Lin H, Wong RP, Martinka M, Li G. 2010. BRG1 expression is increased in human cutaneous melanoma. Br J Dermatol 163: 502-510.
26. Liu X, Tian X, Wang F, Ma Y, Kornmann M, Yang Y. 2014. BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling. Eur J Cancer 50: 2251-2262.
27. Matthaei H, Norris AL, Tsiatis AC, Olino K, Hong SM, dal Molin M, Goggins MG, Canto M, Horton KM, Jackson KD, et al. Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 255: 326-333.
28. Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, Abbruzzese JL, Chiao PJ. 2008. LY2109761, a novel transforming growth factor p receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 7: 829-840.
29. Mi H, Muruganujan A, Thomas PD. 2013. PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res 41: D377-D386.
30. Mino-Kenudson M, Fernandez-del Castillo C, Baba Y, Valsangkar NP, Liss AS, Hsu M, Correa-Gallego C, Ingkakul T, Perez Johnston R, Turner BG, et al. 2011. Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut 60: 1712-1720.
31. Morris JP IV, Wang SC, Hebrok M. 2010. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 10: 683-695.
32. Naidu SR, Love IM, Imbalzano AN, Grossman SR, Androphy EJ. 2009. The SWI/SNF chromatin remodeling subunit BRG1 is a critical regulator of p53 necessary for proliferation of malignant cells. Oncogene 28: 2492-2501.
33. Numata M, Morinaga S, Watanabe T, Tamagawa H, Yamamoto N, Shiozawa M, Nakamura Y, Kameda Y, Okawa S, Rino Y, et al. 2013. The clinical significance of SWI/SNF complex in pancreatic cancer. Int J Oncol 42: 403-410.
34. Ostapoff KT, Cenik BK, Wang M, Ye R, Xu X, Nugent D, Hago- pian MM, Topalovski M, Rivera LB, Carroll KD, et al. 2014. Neutralizing murine TGFpR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis. Cancer Res 74: 4996-5007.
35. Pal S, Yun R, Datta A, Lacomis L, Erdjument-Bromage H, Kumar J, Tempst P, Sif S. 2003. mSin3A/histone deacetylase 2- and PRMT5-containing Brg1 complex is involved in transcriptional repression of the Myc target gene cad. Mol Cell Biol 23: 7475-7487.
36. Park JY, Hong SM, Klimstra DS, Goggins MG, Maitra A, Hruban RH. 2011. Pdx1 expression in pancreatic precursor lesions and neoplasms. Appl Immunohistochem Mol Morphol 19: 444-449.
37. Poultsides GA, Reddy S, Cameron JL, Hruban RH, Pawlik TM, Ahuja N, Jain A, Edil BH, Iacobuzio-Donahue CA, Schulick RD, et al. 2010. Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann Suig 251: 470-476.
38. Reichert M, Rustgi AK. 2011. Pancreatic ductal cells in development, regeneration, and neoplasia. J Clin Invest 121: 4572-4578.
39. Reichert M, Takano S, Heeg S, Bakir B, Botta GP, Rustgi AK. 2013a. Isolation, culture and genetic manipulation of mouse pancreatic ductal cells. Nat Protoc 8: 1354-1365.
40. Reichert M, Takano S, von Burstin J, Kim SB, Lee JS, Ihida-Stans- bury K, Hahn C, Heeg S, Schneider G, Rhim AD, et al. 2013b. The Prrx1 homeodomain transcription factor plays a central role in pancreatic regeneration and carcinogenesis. Genes Dev 27: 288-300.
41. Ryan DP, Hong TS, Bardeesy N. 2014. Pancreatic adenocarcinoma. NEngl J Med 371: 1039-1049.
42. Sahai V, Kumar K, Knab LM, Chow CR, Raza SS, Bentrem DJ, Ebine K, Munshi HG. 2014. BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen. Mol Cancer Ther 13: 1907-1917.
43. Sentani K, Oue N, Kondo H, Kuraoka K, Motoshita J, Ito R, Yoko- zaki H, Yasui W. 2001. Increased expression but not genetic alteration of BRG1, a component of the SWI/SNF complex, is associated with the advanced stage of human gastric carcinomas. Pathobiology 69: 315-320.
44. Shain AH, Pollack JR. 2013. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS One 8: e55119.
45. Shain AH, Giacomini CP, Matsukuma K, Karikari CA, Bashyam MD, Hidalgo M, Maitra A, Pollack JR. 2012. Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Proc Natl Acad Sci 109: E252-E259.
46. Sharma A, Zangen DH, Reitz P, Taneja M, Lissauer ME, Miller CP, Weir GC, Habener JF, Bonner-Weir S. 1999. The homeo- domain protein IDX-1 increases after an early burst of proliferation during pancreatic regeneration. Diabetes 48: 507-513.
47. Siegel R, Ma J, Zou Z, Jemal A. 2014. Cancer statistics, 2014. CA Cancer J Clin 64: 9-29.
48. Sif S, Saurin AJ, Imbalzano AN, Kingston RE. 2001. Purification and characterization of mSin3A-containing Brg1 and hBrm chromatin remodeling complexes. Genes Dev 15: 603-618.
49. Sinn M, Denkert C, Striefler JK, Pelzer U, Stieler JM, Bahra M, Lohneis P, Dorken B, Oettle H, Riess H, et al. 2014. a-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. Br J Cancer 111: 1917-1923.
50. Stanger BZ, Hebrok M. 2013. Control of cell identity in pancreas development and regeneration. Gastroenterology 144: 1170-1179.
51. Sun A, Tawfik O, Gayed B, Thrasher JB, Hoestje S, Li C, Li B. 2007. Aberrant expression of SWI/SNF catalytic subunits BRG1/ BRM is associated with tumor development and increased invasiveness in prostate cancers. Prostate 67: 203-213.
52. Thuault S, Tan EJ, Peinado H, Cano A, Heldin CH, Moustakas A. HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. J Biol Chem 283: 33437-33446.
53. Trapnell C, Pachter L, Salzberg SL. 2009. TopHat: discovering splice junctions with RNA-seq. Bioinformatics 25: 1105-1111.
54. Trotter KW, Archer TK. 2008. The BRG1 transcriptional coregulator. Nucl Recept Signal 6: e004.
55. von Figura G, Fukuda A, Roy N, Liku ME, Morris Iv JP, Kim GE, Russ HA, Firpo MA, Mulvihill SJ, Dawson DW, et al. 2014. The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma. Nat Cell Biol 16: 255-267.
56. Watanabe H, Saito H, Ueda J, Evers BM. 2008. Regulation of pancreatic duct cell differentiation by phosphatidylinositol-3 kinase. Biochem Biophys Res Commun 370: 33-37.
57. Watanabe S, Ueda Y, Akaboshi S, Hino Y, Sekita Y, Nakao M. HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am J Pathol 174: 854-868.
58. Yang L, Pang Y, Moses HL. 2010. TGF-p and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 31: 220-227.
59. Zha L, Zhang J, Tang W, Zhang N, He M, Guo Y, Wang Z. 2013. HMGA2 elicits EMT by activating the Wnt/p-catenin pathway in gastric cancer. Dig Dis Sci 58: 724-733.
60. Zhang Y, Morris JP IV, Yan W, Schofield HK, Gurney A, Simeone DM, Millar SE, Hoey T, Hebrok M, Pasca di Magliano M. Canonical wnt signaling is required for pancreatic carcinogenesis. Cancer Res 73: 4909-4922.
61. Zhang X, Li B, Li W, Ma L, Zheng D, Li L, Yang W, Chu M, Chen W, Mailman RB, et al. 2014. Transcriptional repression by the BRG1-SWI/SNF complex affects the pluripotency of human embryonic stem cells. Stem Cell Reports 3: 460-474.
62. Zhu L, Shi G, Schmidt CM, Hruban RH, Konieczny SF. 2007. Acinar cells contribute to the molecular heterogeneity of pancreatic intraepithelial neoplasia. Am J Pathol 171: 263-273